Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.62 |
| ▸ | JAK3 | P52333 | 14/20 | 0.62 |
| ▸ | JAK1 | P23458 | 13/20 | 0.62 |
| ▸ | TYK2 | P29597 | 9/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376865 | 1.00 | JAK2 (0.62) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4064021 | 0.91 | JAK1 (0.52) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4072654 | 0.90 | JAK3 (0.51) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4072912 | 0.90 | BTK (0.51) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4072931 | 0.89 | JAK3 (0.50) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4068075 | 0.89 | JAK1 (0.49) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4073198 | 0.88 | JAK3 (0.48) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4073742 | 0.88 | JAK1 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL5338094 | 0.87 | JAK3 (0.50) | JAK2JAK3JAK1TYK2CYP1A2 | |
| SCHEMBL4066497 | 0.87 | JAK3 (0.56) | JAK2JAK3JAK1TYK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | claimed |
| CN-115038703-B | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11827598-B1 | Preparation method of tofacitinib citrate | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | AARTI PHARMALABS LIMITED (IN) | 2022-12-22 | — | — | US | disclosed |
| CN-115038703-A | Preparation method of tofacitinib and intermediate product thereof | 阿尔第实业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4051681-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | Aarti Industries Limited (IN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021084556-A1 | Process for the preparation of tofacitinib and intermediates thereof | AARTI INDUSTRIES LIMITED (IN) | 2021-05-06 | — | — | WO | disclosed |
| EP-3539965-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LAB LTD (IN) | 2021-01-20 | — | — | EP | disclosed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | disclosed |
| EP-3539965-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (3R,4R)-(1-BENZYL-4-METHYLPIPERIDIN-3-YL)-METHYLAMINE | UNICHEM LABORATORIES LIMITED (IN) | 2019-09-18 | — | — | EP | disclosed |
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | PFIZER INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8232394-B2 | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-1451192-B1 | NOVEL CRYSTALLINE COMPOUND | PFIZER PROD INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7803805-B2 | Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt | PFIZER INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-6965027-B2 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate | PFIZER INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050159434-A1 | Novel crystalline compound | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| EP-1451192-A1 | NOVEL CRYSTALLINE COMPOUND | Pfizer Products Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030130292-A1 | Novel crystalline compound | PFIZER INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003048162-A1 | NOVEL CRYSTALLINE COMPOUND | PFIZER PRODUCTS INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | DPYD, CPS1, TYMS | JAK2 216/4885JAK3 323/4885JAK1 513/4885 |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | KDM4D, KDM4A, KDM4C | JAK2 1226/4885JAK3 1107/4885JAK1 1103/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | JAK2 238/4885JAK3 351/4885JAK1 547/4885 |
| US-11827598-B1 | Preparation method of tofacitinib citrate | JAK3, JAK2, JAK1 | JAK2 2/4885JAK3 1/4885JAK1 3/4885 |
| US-20050159434-A1 | Novel crystalline compound | ACP1, PLK4, PACSIN2 | JAK2 1479/4885JAK3 1149/4885JAK1 946/4885 |
| US-20030130292-A1 | Novel crystalline compound | ACP1, PACSIN2, PLK4 | JAK2 1328/4885JAK3 1054/4885JAK1 959/4885 |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | MCCC2, JAK1, JAK3 | JAK2 12/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.